The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Abstract
Purpose: Phosphatidylinositol 3-kinase (PI3K) signaling is critical for the proliferation and survival of malignant B cells. Copanlisib, a pan-class I PI3K inhibitor with predominant activity against PI3K-α and -δ isoforms, has demonstrated efficacy and a manageable safety profile in patients with indolent lymphoma. Patients and Methods: In this phase II study, 142 patients with relapsed or refractory indolent lymphoma after two or more lines of therapy were enrolled to receive copanlisib 60 mg intravenously on days 1, 8, and 15 of a 28-day cycle. The primary end point was objective response rate; secondary end points included duration of response, progression-free survival, and overall survival. In addition, safety and gene expression were evaluated. Results: Median age was 63 years (range, 25 to 82 years), and patients had received a median of three (range, two to nine) prior regimens. The objective response rate was 59% (84 of 142 patients); 12% of patients achieved a complete response. Median time to response was 53 days. Median duration of response was 22.6 months, median progression-free survival was 11.2 months, and median overall survival had not yet been reached. The most frequent treatment-emergent adverse events were transient hyperglycemia (all grades, 50%; grade 3 or 4, 41%) and transient hypertension (all grades, 30%; grade 3, 24%). Other grade ≥3 events included decreased neutrophil count (24%) and lung infection (15%). High response rates to copanlisib were associated with high expression of PI3K/B-cell receptor signaling pathway genes. Conclusion: PI3K-α and -δ inhibition by copanlisib demonstrated significant efficacy and a manageable safety profile in heavily pretreated patients with relapsed or refractory indolent lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationA Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“of patients 142 Male sex 71 (50) Median age, years (range) 63 (25-82) Race* White 120 (85) Asian 15 (11) Histology of tumor† FL 104 (73) Grade 1 22 (21) Grade 2 52 (50) Grade 3a 27 (26) MZL 23 (16) SLL 8 (6) LPL/WM 6 (4) DLBCL‡ 1 (1) Baseline ECOG performance status 0 (fully active) 80 (56) 1 (restricted active) 57 (4…”
BackgroundPI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Self-citationPhosphoinositide 3-kinase: the key switch mechanism in insulin signalling
SHEPHERD, P. R., WITHERS, D. J., & SIDDLE, K. (1998) · Biochemical Journal · doi:10.1042/bj3330471 · Cited by 953
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Sarker, D., Ang, J. E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P. A., Raynaud, F. I., Levy, G., Ware, J. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0947 · Cited by 313
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00591-x · Cited by 666
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J. C., Bachy, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01622-0 · Cited by 555
Self-citationBudde, L. E., Sehn, L. H., Matasar, M., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00335-7 · Cited by 461
Self-citationMarginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Zucca, E., Arcaini, L., Buske, C., Johnson, P. W., Ponzoni, M., Raderer, M., Ricardi, U., Salar, A., Stamatopoulos, K., Thieblemont, C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.010 · Cited by 350
Progress in the mechanism and targeted drug therapy for COPD
Wang, C., Zhou, J., Wang, J., Li, S., Fukunaga, A., Yodoi, J., & Tian, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00345-x · Cited by 303
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 302
Carbone, A., Roulland, S., Gloghini, A., Younes, A., von Keudell, G., López-Guillermo, A., & Fitzgibbon, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0132-x · Cited by 278
Dreyling, M., Ghielmini, M., Rule, S., Salles, G., Ladetto, M., Tonino, S. H., Herfarth, K., Seymour, J. F., & Jerkeman, M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.008 · Cited by 270
Self-citationFollicular lymphoma: 2020 update on diagnosis and management
Freedman, A., & Jacobsen, E. (2020) · American Journal of Hematology · doi:10.1002/ajh.25696 · Cited by 268
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Mayer, J., Merli, M., Lunin, S. D., Pettitt, A. R., Nagy, Z., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00915 · Cited by 264
Self-citationNovel roles of phosphoinositides in signaling, lipid transport, and disease
Hammond, G. R. V., & Burke, J. E. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2019.12.007 · Cited by 203
Sehn, L. H., Bartlett, N. L., Matasar, M. J., Schuster, S. J., Assouline, S. E., Giri, P., Kuruvilla, J., Shadman, M., Cheah, C. Y., Dietrich, S., et al. (2025) · Blood · doi:10.1182/blood.2024025454 · Cited by 94
Self-citationRecent advances of tanshinone in regulating autophagy for medicinal research
Wu, S., Zhao, K., Wang, J., Liu, N., Nie, K., Qi, L., & Xia, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1059360 · Cited by 32
Cheung, Y.-M. M., McDonnell, M., & Hamnvik, O.-P. R. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100776 · Cited by 21
Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
Sun, K., Jin, L., Karolová, J., Vorwerk, J., Hailfinger, S., Opalka, B., Zapukhlyak, M., Lenz, G., & Khandanpour, C. (2023) · Cancers · doi:10.3390/cancers15082373 · Cited by 9
Self-citation
Metadata
- Authors
- Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G. A., Lenz, G., Kim, W. S., Nagler, A., Panayiotidis, P., Demeter, J., Özcan, M., Kosinova, M., Bouabdallah, K., Morschhauser, F., Stevens, D. A., Trevarthen, D., Giurescu, M., Cupit, L., Liu, L., Köchert, K., Seidel, H., Peña, C., Yin, S., Hiemeyer, F., Garcia-Vargas, J., Childs, B. H., & Zinzani, P. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-12-10
- Volume
- 35
- Issue
- 35
- Pages
- 3898-3905
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2762226752
- Cited by
- 395
- References
- 23
- FWCI
- 25.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.